RA
DFTX

Rosalind Advisors’s Definium Therapeutics DFTX Stock Holding History

Rosalind Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.36M Sell
125,000
-625,000
-83% -$10.6M 0.95% 24
2025
Q4 		$10M Hold
750,000
– – 3.53% 15
2025
Q3 		$8.84M Buy
750,000
+330,000
+79% +$3.08M 3.02% 15
2025
Q2 		$2.73M Hold
420,000
– – 1.29% 22
2025
Q1 		$2.46M Buy
+420,000
New +$3.01M 1.19% 23

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Rosalind Advisors's DFTX Position: Q1 2026 in Review

Rosalind Advisors reduced its Definium Therapeutics (DFTX) stake by 83% in Q1 2026, selling an estimated $10.6M and leaving 125,000 shares worth $2.36M. The position accounts for 0.95% of the portfolio, ranked #24.

Rosalind Advisors first reported a position in DFTX in Q1 2025 and has held it in 5 quarters since. The position peaked at $10M in Q4 2025. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • Rosalind Advisors held 125,000 shares of Definium Therapeutics worth $2.36M as of Q1 2026.
  • Rosalind Advisors sold 625,000 Definium Therapeutics shares in Q1 2026, an estimated $10.6M.
  • Definium Therapeutics made up 0.95% of Rosalind Advisors's portfolio in Q1 2026, its #24 holding.
  • Rosalind Advisors first reported a position in Definium Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Rosalind Advisors's Definium Therapeutics position peaked at $10M in Q4 2025.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Rosalind Advisors's 13F filing for Q1 2026, filed 14 May 2026.